Every 10-Q that BALANCE LABS INC (BLNC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BLNC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BLNC filings page.
Balance Labs, Inc. reported minimal operating scale for the quarter ended June 30, 2026. The company generated $7,333 in quarterly consulting revenue and $40,000 for the six months, but incurred operating expenses of $1,028,644, leading to a loss from operations of $988,644 for the first half of 2026.
A large non-cash gain of $982,505 from remeasurement of a derivative liability tied to the CEO’s anti-dilution right reduced the six‑month net loss to $59,038. However, the balance sheet remains highly stressed, with cash of only $117,465, total assets of $126,771, total liabilities of $2,900,185, and a stockholders’ deficit of $2,773,414 as of June 30, 2026.
Management discloses substantial doubt about the company’s ability to continue as a going concern, citing a working capital deficit of $2,773,414, accumulated deficit of $37,710,684, and defaulted debt, including a $25,000 convertible note and related-party notes totaling $500,000. Internal controls over financial reporting are described as ineffective, with material weaknesses in formal controls, audit committee oversight, and segregation of duties. A subsequent $20,000‑per‑month consulting contract beginning July 2026 modestly enhances prospective revenue but does not resolve the liquidity challenge.
Balance Labs, Inc. reported a small net income of $177,803 for the quarter ended March 31, 2026, driven mainly by a non-cash gain of $706,056 from remeasuring a derivative tied to the CEO’s anti-dilution provision. Core operations remain weak, with revenue of $32,667 from a single advisory client and a loss from operations of $488,087, including $329,153 of stock-based compensation.
Cash used in operations was $142,609, leaving cash of $216,366 and a working capital deficit of $2,869,383 as of quarter-end. The company discloses substantial doubt about its ability to continue as a going concern without new financing and notes related-party debt of $500,000 that matured in May 2026 and remains outstanding, as well as a long‑defaulted $25,000 convertible note. Management also reports material weaknesses in internal controls, including limited formalized controls, no audit committee, and inadequate segregation of duties.
Balance Labs, Inc. reported a larger net loss as it restructured leadership and recognized a new derivative tied to its CEO agreement. Net loss was $3,594,664 for Q3 2025 (basic and diluted EPS $0.16 loss) and $3,747,212 for the nine months ended September 30, 2025. Operating cash outflow was $93,487 for the nine months.
Liquidity remains strained: cash was $4,512 as of September 30, 2025, with a working capital deficit of $8,675,685 and an accumulated deficit of $9,630,533. Management disclosed substantial doubt about continuing as a going concern. A derivative liability of $3,297,695 was recognized from an anti‑dilution feature in the CEO’s employment agreement, with a $3,425,796 loss recognized and a $128,101 remeasurement gain in the quarter.
The company issued 780,264 shares to its CEO as part of an initial equity grant, recognizing $142,633 in stock‑based compensation in Q3. As a subsequent event, outstanding debt totaling $4,166,946.69 was converted into common stock at $0.25 per share, and the Board approved additional equity issuances at the same price. Shares outstanding were 46,852,319 as of November 13, 2025.